Funds and ETFs Santen Pharmaceutical Co., Ltd.

4536

JP3336000009

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	1.22%	15 M€	+7.34%
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.19%	1,120 M€	+0.40%
DAIWA ETF MSCI JAPAN ESG SELECT LEADERS INDEX ETF - JPY	0.13%	81 M€	+14.05%
NOMURA NEXT FUNDS MSCI JAPAN EMPOWERING WOMEN SELECT INDEX ETF - JPY	0.13%	60 M€	+14.42%
NOMURA NEXT FUNDS NOMURA ENTERPRISE VALUE ALLOCATION INDEX ETF - JPY	0.11%	73 M€	+11.61%
DAIWA ETF MSCI JAPAN EMPOWERING WOMEN INDEX ETF - JPY	0.10%	4 M€	+13.95%
DAIWA ETF FTSE BLOSSOM JAPAN INDEX ETF - JPY	0.10%	14 M€	+15.63%
NOMURA NEXT FUNDS JPX-NIKKEI INDEX 400 ETF - JPY	0.09%	10,207 M€	+14.32%
MAXIS JPX-NIKKEI 400 ETF - JPY	0.09%	5,115 M€	+13.58%
NZAM ETF TOPIX EX-FINANCIALS - JPY	0.08%	18 M€	+16.15%	-
MAXIS TOPIX ETF - JPY	0.07%	20,721 M€	+13.52%	-
NOMURA TOPIX EXCHANGE TRADED FUND ETF - JPY	0.07%	144,586 M€	+14.49%
DAIWA ETF TOPIX ETF - JPY	0.07%	66,066 M€	+14.68%	-
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD	0.06%	773 M€	-.--%	-
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	10 M€	-3.35%	-
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.02%	205 M€	-.--%
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.01%	7 M€	+1.95%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.01%	31 M€	+3.50%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.00%	389 M€	+6.83%	-

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,512 JPY

Average target price

1,767 JPY

Spread / Average Target

+16.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANTEN PHARMACEUTICAL CO., LTD.	+7.65%	3.5B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,512 ^JPY	+1.41%		+4.13%	+7.65%

Mar. 26	Santen Pharmaceutical to Cancel 12 Million Treasury Shares	MT
Mar. 25	Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	CI